Generic Medicine Info
Severe hepatic impairment; hypoalbuminaemia; primary biliary cirrhosis; gallbladder disease; pregnancy; lactation.
Special Precautions
Renal impairment; discontinue if myotoxicity is suspected or creatine kinase concentration increases significantly. May increase lithogenic index.
Adverse Reactions
Anorexia; nausea; gastric discomfort; headache; dizziness; vertigo; fatigue; skin reactions; alopoecia; impotence; anaemia; leucopenia; myotoxicity; thrombocytopenia.
Drug Interactions
May enhance the effects of oral anticoagulants. May alter glucose tolerance in diabetics, thus dosage of antidiabetics may need to be adjusted. Concurrent admin with ciclosporin may lead to increased ciclosporin concentrations and renal toxicity.
Potentially Fatal: Increased risk of myopathy when used with statins.
Lab Interference
Raised serum aminotransferase and creatine phosphokinase concentrations.
Description: Simfibrate is a fibric acid derivative that is used in the treatment of hyperlipidaemias.
MIMS Class
Dyslipidaemic Agents
Disclaimer: This information is independently developed by MIMS based on Simfibrate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in